In This Article:
DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon’s proprietary GOLDILOCKS™ transposase-based platform.
This collaboration enables clients to integrate with Scorpius’ program management team and quality system while preparing to transfer a research cell bank (RCB) to the Company’s facilities in San Antonio, TX, for further biomanufacturing work. In addition to full-scale cell line development services, Celltheon offers Scorpius clients services in antibody discovery, variant screening and development, and comparability studies. The first client signed under this partnership aims to scale up to GMP manufacturing with Scorpius.
Jeff Wolf, CEO of Scorpius, commented, “We are excited to collaborate with Celltheon, a partner that shares Scorpius’ mission to deliver responsive, high-quality, flexible services to early-stage biotechs and academic researchers. This partnership allows our clients to secure their supply chain and intellectual property by working with Celltheon, a California-based company, and then transferring their high-expressing, stable cell line to our state-of-the-art GMP facility in Texas to continue manufacturing.”
“We look forward to helping Scorpius clients overcome their early development challenges so they can seamlessly move to GMP activity. Together, Celltheon and Scorpius are committed to ensuring that the next generation of biotherapeutics get to patients faster and more affordably,” added Divya Goel, VP of Business Development and Board Member at Celltheon.
Celltheon
Celltheon develops leading edge technologies and innovative solutions for the next generation of biotherapeutics. Celltheon offers platformed and custom end-to-end solutions for drug developability, cell line development, and process development to its clients, to bridge the gap between early drug development and manufacturing. For more information, please visit www.celltheon.com.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.